Multiple myeloma-associated AL amyloidosis: Is a distinctive therapeutic approach warranted?

Bone Marrow Transplantation

Volumn 38, Issue 1, 2006, Pages 7-15

  Bahlis, N J ^a   Lazarus, H M ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Amyloidosis; Multiple myeloma; Transplant

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CARMUSTINE; COLCHICINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; TROPONIN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BRADYCARDIA; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG FATALITY; GENETIC ANALYSIS; HEART AMYLOIDOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORTALITY; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

AMYLOIDOSIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 33745281214     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705395     Document Type: Review

References (52)

1. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998; 82: 1501-1505.
2. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999; 13: 1211-1233, ix.
3. Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997; 27: 315-319.
4. Phillips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study. Biol Blood Marrow Transplant 2004; 10: 473-483.
5. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731-735.
6. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282.
7. Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E et al. Holter monitoring in AL amyloidosis: Prognostic implications. Pacing Clin Electrophysiol 2001; 24: 1228-1233.
8. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949-2951.
9. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596.
10. Paccalin M, Hachulla E, Cazalet C, Tricot L, Carreiro M, Rubi M et al. Localized amyloidosis: A survey of 35 French cases. Amyloid 2005; 12: 239-245.
11. Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: A valuable tool in primary systemic amyloidosis. Blood 1989; 74: 1108-1111.
12. Perfetti V, Bellotti V, Garini P, Zorzoli I, Rovati B, Marinone MG et al. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab Invest 1994; 71: 853-861.
13. Perfetti V, Ubbiali P, Magni M, Colli VM, Casarini S, Matteucci P et al. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplant 1999; 23: 323-327.
14. Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Larson DR, Therneau TM et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 1998; 103: 704-710.
15. Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001; 98: 2266-2268.
16. Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S et al. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol 2001; 158: 1599-1603.
17. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
18. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2005, 346-352.
19. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105: 794-803.
20. Haubitz M, Peest D. Myeloma-new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 2006; 21: 582-590.
21. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822-824.
22. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
23. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
24. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
25. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Auto-greffe. J Clin Oncol 2005; 23: 9227-9233.
26. Blade J, Rosinol L, Sureda A, Ribera JM, az-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759.
27. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
28. Cavo M. Update on high dose therapy - Italian studies. Haematologica 2005; 90: 39 (abstract PL8.04).
29. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.
30. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998; 91: 3662-3670.
31. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025-1031.
32. Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271-277.
33. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: A single centre prospective phase II study. Br J Haematol 2004; 127: 543-551.
34. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004; 140: 85-93.
35. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998; 101: 766 769.
36. Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): An Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34: 149-154.
37. Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C et al. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: The Calgary BMT Program experience. Bone Marrow Transplant 2005; 36: 591-596.
38. Schonland SO, Perz JB, Hundemer M, Hegenbart U, Kristen AV, Hund E et al. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005; 80: S160-S163.
39. Gillmore J. High dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA (eds). Amyloidand Amyloidosis. Parthenon Publishing: Pearl River, NY, 1999, p 102.
40. Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D et al. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2006; 37: 937-943.
41. Vesole D, Perez W, Reece D, Akasheh M, Horowitz M, Bredeson C. High dose therapy with autologous hematopoietic stem cell transplantation (HSCT) for patients with primary systemic amyloidosis (AL): Results from the autologous blood and marrow transplant registry (ABMTR). Blood 2003; 102: (abstract 402).
42. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood 2004; 103: 3960-3963.
43. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (Primary) amyloidosis: results of the french multicentric randomized trial (MAG and IFM Intergroup). Blood 2005; 106: 127a (abstract 421).
44. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
45. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
46. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003; 101: 827-830.
47. Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: The first step towards an 'operational cure'? Bone Marrow Transplant 2002; 30: 479-484.
48. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and auto-transplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
49. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: A single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
50. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-3779.
51. Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002; 116: 202-210.
52. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381-388.